NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease<
17 Oct 2023

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties
Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023<
16 Oct 2023

Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023

Lipidated IL-22 induced dose-dependent reductions in body weight and blood glucose and improvement
VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility<
12 Oct 2023

VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility

Dr. Jeffrey Lawson will assume the role of CEO, succeeding Dr. Jan Öhrström who will continue as Chairman.
Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment<
12 Oct 2023

Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment

The newly granted patents join a list of 17 issued patents for Anaconda Biomed.
AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia<
11 Oct 2023

AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia

Ilofotase alfa demonstrates pharmacologically relevant effect on disease specific biomarkers

CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris<
09 Oct 2023

CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris

The company occupies over 2,400m² of production, laboratory, and office space.
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments<
03 Oct 2023

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development, Mark Plavsic, Ph.D., Appointed as Chief Technology Officer
Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients<
28 Sep 2023

Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients

Spain is the first country in the world to have this technology
SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics<
26 Sep 2023

SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics

Milestone broadens partnership to develop novel ocular therapies using CRISPR-based technologies

CorWave announces the appointment of Magalie Durrèche as Chief Financial Officer<
26 Sep 2023

CorWave announces the appointment of Magalie Durrèche as Chief Financial Officer

Magalie Durrèche has over twenty years of experience in corporate finance, mainly in the industrial sector

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка